Cargando…
Treatment with senicapoc in a porcine model of acute respiratory distress syndrome
BACKGROUND: Senicapoc is a potent and selective blocker of KCa3.1, a calcium-activated potassium channel of intermediate conductance. In the present study, we investigated whether there is a beneficial effect of senicapoc in a large animal model of acute respiratory distress syndrome (ARDS). The pri...
Autores principales: | Petersen, Asbjørn G., Lind, Peter C., Jensen, Anne-Sophie B., Eggertsen, Mark A., Granfeldt, Asger, Simonsen, Ulf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053424/ https://www.ncbi.nlm.nih.gov/pubmed/33870468 http://dx.doi.org/10.1186/s40635-021-00381-z |
Ejemplares similares
-
A validated UHPLC-MS/MS method for rapid determination of senicapoc in plasma samples
por: Sørensen, Lambert K., et al.
Publicado: (2021) -
Effect of the KCa3.1 blocker, senicapoc, on cerebral edema and cardiovascular function after cardiac arrest — A randomized experimental rat study
por: Hansen, Frederik Boe, et al.
Publicado: (2021) -
Senicapoc treatment in COVID‐19 patients with severe respiratory insufficiency—A randomized, open‐label, phase II trial
por: Granfeldt, Asger, et al.
Publicado: (2022) -
Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments
por: Phua, Jie Liang, et al.
Publicado: (2018) -
Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease
por: Jin, Lee‐Way, et al.
Publicado: (2019)